4.1 Autonomic and Central Nervous System Pharmacology

4.1 Autonomic and Central Nervous System Pharmacology

The autonomic nervous system (ANS) and central nervous system (CNS) coordinate involuntary physiological homeostasis, neuroendocrine regulation, cognition, and motor control. A thorough mastery of receptor subtype signaling, neurotransmitter life cycles, and neuropharmacological drug actions is a foundational core of the PEBC Evaluating Examination.

---

1. Autonomic Nervous System Organization and Signal Transduction

The ANS comprises the sympathetic (thoracolumbar) and parasympathetic (craniosacral) divisions, functioning through distinct preganglionic and postganglionic neurotransmitters and receptor superfamilies.

+--------------------------------------------------------------------------------------+
|                      AUTONOMIC NEUROTRANSMISSION PATHWAYS                            |
+--------------------------------------------------------------------------------------+
|  PARASYMPATHETIC:                                                                    |
|  [CNS] ===(ACh)===> [Ganglionic Nn Receptor] ===(ACh)===> [Effector Muscarinic (M)]  |
|                                                                                      |
|  SYMPATHETIC:                                                                        |
|  [CNS] ===(ACh)===> [Ganglionic Nn Receptor] ===(NE)===> [Effector Adrenoceptors]    |
|                                                  |         (alpha-1, beta-1, beta-2) |
|                                                  +===(ACh)===> [Sweat Glands (M3)]   |
|                                                  +===(DA)===> [Renal Vasculature(D1)]|
|                                                                                      |
|  ADRENAL MEDULLA:                                                                    |
|  [CNS] ===(ACh)===> [Chromaffin Cell Nn] ===> [Epinephrine (80%) + NE (20%) in Blood]|
|                                                                                      |
|  SOMATIC MOTOR:                                                                      |
|  [CNS Motoneuron] =========================(ACh)=========================> [Nm / NMJ]|
+--------------------------------------------------------------------------------------+

Adrenoceptor Subtypes and G-Protein Coupling

Adrenoceptors are 7-transmembrane G-protein coupled receptors (GPCRs) responsive to endogenous catecholamines (norepinephrine and epinephrine):

$$\begin{aligned} \mathbf{G_q \text{ Coupling (}\alpha_1\text{)}} &\implies \uparrow \text{Phospholipase C (PLC)} \to \uparrow \text{IP}_3 + \text{DAG} \to \uparrow [\text{Ca}^{2+}]_i \to \text{Smooth Muscle Contraction} \\ \mathbf{G_i \text{ Coupling (}\alpha_2\text{)}} &\implies \downarrow \text{Adenylyl Cyclase (AC)} \to \downarrow \text{cAMP} + \downarrow \text{PKA} \to \text{Inhibition of Transmitter Release} \\ \mathbf{G_s \text{ Coupling (}\beta_1, \beta_2, \beta_3\text{)}} &\implies \uparrow \text{Adenylyl Cyclase (AC)} \to \uparrow \text{cAMP} \to \uparrow \text{Protein Kinase A (PKA)} \end{aligned}$$

Cholinergic Receptors: Muscarinic and Nicotinic Subtypes

• Muscarinic GPCRs:
  • $M_1, M_3, M_5$ ($G_q$): Mediate exocrine glandular secretion (salivation, lacrimation, sweating), gastrointestinal smooth muscle contraction, bronchial constriction, and pupillary sphincter contraction (miosis). $M_3$ stimulation on vascular endothelial cells stimulates endothelial nitric oxide synthase (eNOS), releasing nitric oxide (NO) and causing paradoxical vasodilation.
  • $M_2, M_4$ ($G_i$): $M_2$ receptors are localized on the sinoatrial and atrioventricular nodes, opening inward-rectifying $\text{K}^+$ channels ($I_{K,\text{ACh}}$) and decreasing cAMP, producing negative chronotropy, negative dromotropy, and decreased atrial inotropy.
• Nicotinic Ligand-Gated Ion Channels:
  • $N_M$ (Neuromuscular junction): Pentameric $(\alpha_1)_2\beta_1\gamma\delta$ ion channels. Acetylcholine binding allows rapid $\text{Na}^+$ influx and $\text{K}^+$ efflux, causing endplate potential depolarization and skeletal muscle contraction.
  • $N_N$ (Autonomic ganglia and adrenal medulla): Mediates trans-synaptic transmission across all autonomic ganglia.

---

2. Autonomic Pharmacology: Therapeutic Drug Classes

+--------------------------------------------------------------------------------------+
|                       AUTONOMIC DRUG CLASSIFICATION MATRIX                           |
+--------------------------------------------------------------------------------------+
|  CHOLINERGIC AGENTS:                                                                 |
|  - Direct Agonists       : Bethanechol (bladder atony), Pilocarpine (glaucoma)       |
|  - AChE Inhibitors       : Donepezil, Rivastigmine, Pyridostigmine, Neostigmine      |
|  - Antimuscarinics       : Atropine, Ipratropium, Tiotropium, Oxybutynin, Glycopyrrolate|
|                                                                                      |
|  ADRENERGIC AGENTS:                                                                  |
|  - Non-Selective Agonists: Epinephrine (alpha-1, alpha-2, beta-1, beta-2), NE       |
|  - Beta-Blockers (Selective): Bisoprolol, Metoprolol, Atenolol (Cardioselective)    |
|  - Beta-Blockers (Non-Sel): Propranolol, Timolol, Nadolol                           |
|  - Alpha-Beta Blockers   : Carvedilol, Labetalol                                     |
|  - Alpha-1 Blockers      : Tamsulosin (BPH), Prazosin, Doxazosin (Antihypertensive)  |
+--------------------------------------------------------------------------------------+

Neuromuscular Blockers and Reversal Strategies

• Depolarizing Blockers (Succinylcholine): Binds $N_M$ receptors and causes persistent endplate depolarization (Phase I block with fasciculations, followed by Phase II desensitization block). Rapid onset ($<60\text{ seconds}$), ultra-short duration ($5-10\text{ minutes}$) metabolized by plasma butyrylcholinesterase (pseudocholinesterase). Adverse effects: Hyperkalemia (hazardous in burn, trauma, or spinal denervation patients due to extrajunctional receptor upregulation), malignant hyperthermia (treated with dantrolene), and prolonged apnea in atypical pseudocholinesterase variants.
• Non-Depolarizing Blockers (Rocuronium, Vecuronium, Cisatracurium): Competitive antagonists at $N_M$ receptors. Cisatracurium undergoes organ-independent Hofmann elimination (spontaneous ester hydrolysis and chemical degradation at physiological pH and temperature), making it the agent of choice in severe renal or hepatic impairment.
• Reversal Agents:
  • Sugammadex: A modified gamma-cyclodextrin that encapsulates and chelates aminosteroid blockers (rocuronium $>$ vecuronium) in plasma at a 1:1 molar ratio, achieving rapid, chemically specific reversal independent of cholinesterase inhibition.
  • Neostigmine + Glycopyrrolate: Neostigmine inhibits AChE to elevate synaptic ACh and competitively displace the blocker; co-administered glycopyrrolate or atropine prevents muscarinic side effects (profound bradycardia, bronchospasm, hypersalivation).

---

3. Central Nervous System Pharmacology: Neurotransmitters and Affective Disorders

GABAergic and Glutamatergic Neurotransmission

                   [GABA-A Receptor: Chloride Ionophore]
                    +---------------------------------+
                    |    Benzodiazepine Site (alpha/gamma)|
                    |    GABA Agonist Site (alpha/beta)   |
                    |    Barbiturate Site (Transmembrane) |
                    |    Picrotoxin / Channel Pore        |
                    +---------------------------------+
                                     |
            +------------------------+------------------------+
            |                                                 |
            v                                                 v
  [Benzodiazepines: Increase Frequency]       [Barbiturates: Increase Duration]
  - Shift GABA curve to the left              - Direct opening at high doses
  - Flumazenil competitive antagonist         - Lower safety margin, respiratory arrest

• $\text{GABA}_A$ Receptor Modulators:
  • Benzodiazepines (Lorazepam, Diazepam, Clonazepam): Bind allosterically to the $\alpha/\gamma$ subunit interface, increasing the frequency of channel opening in response to GABA. Indicated for acute anxiety, panic disorder, alcohol withdrawal, and status epilepticus.
  • Barbiturates (Phenobarbital, Thiopental): Increase the duration of chloride channel opening and can directly open chloride channels at high concentrations without GABA, explaining their narrow therapeutic index and fatal respiratory depression risks.
  • Z-Drugs (Zopiclone, Zolpidem): Selective positive allosteric modulators at $\alpha_1$-containing $\text{GABA}_A$ complexes, delivering hypnotic action with minimal anxiolytic or muscle relaxant effects.
  • $\text{GABA}_B$ Receptor Agonist (Baclofen): Presynaptic $G_i$-coupled GPCR that increases $\text{K}^+$ conductance, hyperpolarizing motor neurons and relieving muscle spasticity.

Antidepressant Pharmacotherapy (CANMAT Guidelines)

According to the Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical Guidelines for Major Depressive Disorder (MDD):

---

4. Antipsychotic Pharmacotherapy and Extrapyramidal Syndromes

+--------------------------------------------------------------------------------------+
|                     DOPAMINE PATHWAYS IN ANTIPSYCHOTIC PHARMACOLOGY                  |
+--------------------------------------------------------------------------------------+
|  1. Mesolimbic Pathway     : Excess DA = Positive symptoms; D2 block = Antipsychotic |
|  2. Mesocortical Pathway   : Deficient DA = Negative/cognitive symptoms              |
|  3. Nigrostriatal Pathway  : D2 block = Extrapyramidal Symptoms (EPS) and Tardive Dysk|
|  4. Tuberoinfundibular     : D2 block = Hyperprolactinemia (galactorrhea, amenorrhea)|
+--------------------------------------------------------------------------------------+

First-Generation (Typical) vs. Second-Generation (Atypical) Antipsychotics

• First-Generation Antipsychotics (FGAs: Haloperidol, Fluphenazine, Chlorpromazine): High-affinity competitive antagonists at dopamine $D_2$ receptors. High-potency agents (haloperidol) carry high rates of extrapyramidal symptoms (EPS) and hyperprolactinemia, but low anticholinergic/sedative liabilities.
• Second-Generation Antipsychotics (SGAs: Olanzapine, Risperidone, Quetiapine, Aripiprazole, Clozapine): Combine $D_2$ antagonism with potent serotonin $5\text{-HT}_{2A}$ antagonism. $5\text{-HT}_{2A}$ blockade stimulates dopamine release in the nigrostriatal tract, mitigating EPS.
  • Aripiprazole / Brexpiprazole / Cariprazine: Partial agonists at $D_2$ and $5\text{-HT}_{1A}$ receptors, acting as functional stabilizers with low metabolic and EPS liabilities.
  • Metabolic Liability Hierarchy: Clozapine $=$ Olanzapine $>$ Quetiapine $\ge$ Risperidone $>$ Lurasidone $=$ Ziprasidone $=$ Aripiprazole.

Extrapyramidal Symptom (EPS) Spectrum and Management

Clozapine Hematologic Surveillance

Clozapine is the gold standard for treatment-resistant schizophrenia (failure of $\ge 2$ adequate antipsychotic trials). It is non-EPS-inducing but carries risks of agranulocytosis ($<1\%$), severe constipation/ileus, myocarditis, and seizures.

• Health Canada and Canadian registry protocols mandate baseline and regular Absolute Neutrophil Count (ANC) monitoring:
  • Mandatory threshold to initiate: $\text{ANC} \ge 2.0 \times 10^9\text{/L}$ (or $\ge 1.5 \times 10^9\text{/L}$ for Benign Ethnic Neutropenia / BEN).
  • If $\text{ANC} < 1.5 \times 10^9\text{/L}$ (mild/moderate neutropenia): Interrupt therapy and monitor daily.
  • If $\text{ANC} < 1.0 \times 10^9\text{/L}$ (severe agranulocytosis): Immediately and permanently discontinue clozapine.

---

5. Antiseizure Medications (ASMs) and Parkinson's Disease Pharmacotherapy

+--------------------------------------------------------------------------------------+
|                     ANTISEIZURE MEDICATIONS MECHANISM MATRIX                         |
+--------------------------------------------------------------------------------------+
|  1. Voltage-Gated Na+ Channel Blockers: Phenytoin, Carbamazepine, Lamotrigine, Lacosamide
|  2. T-Type Ca2+ Channel Blockers     : Ethosuximide (Selective for Absence Seizures) |
|  3. Alpha-2-Delta Ca2+ Ligands       : Gabapentin, Pregabalin (Neuropathic Pain/Adjunct)
|  4. SV2A Vesicular Protein Modulators: Levetiracetam, Brivaracetam                   |
|  5. GABAergic Potentiators           : Valproic Acid, Clobazam, Vigabatrin, Tiagabine|
|  6. Broad-Spectrum Mixed Actions     : Valproic Acid, Topiramate, Zonisamide         |
+--------------------------------------------------------------------------------------+

• Phenytoin: Displays non-linear Michaelis-Menten pharmacokinetics (hepatic CYP2C9/2C19 saturation within therapeutic range $40-80\text{ }\mu\text{mol/L}$ [$10-20\text{ mg/L}$]). Chronic adverse effects: gingival hyperplasia, hirsutism, peripheral neuropathy, cerebellar ataxia, osteomalacia. Highly protein bound ($90\%$ to albumin).
• Carbamazepine: Potent enzyme inducer that exhibits autoinduction of its own CYP3A4-mediated metabolism over the first $2-4\text{ weeks}$. Adverse effects: hyponatremia (SIADH), aplastic anemia, agranulocytosis, and severe cutaneous adverse reactions (SJS/TEN) strongly linked to the HLA-B*1502 allele in Asian ancestry.
• Lamotrigine: Blocks voltage-gated $\text{Na}^+$ channels and suppresses glutamate release. Metabolized primarily via glucuronidation. Drug Interaction: Valproate potently inhibits lamotrigine glucuronidation, doubling its elimination half-life and drastically increasing SJS risk; lamotrigine starting doses must be reduced by $\ge 50\%$.
• Valproic Acid / Divalproex: Broad-spectrum ASM. Blocks $\text{Na}^+$ channels, increases GABA levels (inhibits GABA transaminase and succinic semialdehyde dehydrogenase), and blocks T-type $\text{Ca}^{2+}$ currents. Adverse effects: Hepatotoxicity, acute pancreatitis, hyperammonemia, weight gain, alopecia, thrombocytopenia, and severe teratogenicity (neural tube defects; avoid in women of childbearing potential).
• Ethosuximide: Selectively blocks low-voltage-activated T-type calcium channels in thalamocortical relay neurons, disrupting the synchronized $3\text{-Hz}$ spike-and-wave rhythm of generalized absence seizures.